HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial.

AbstractBACKGROUND AND PURPOSE:
The efficacy of the antiplatelet agent triflusal for prevention of vascular events after stroke has been reported in a pilot study. However, there is a need to confirm those results in a larger study.
METHODS:
We performed a randomized, double-blind, multicenter study to test the efficacy of triflusal (600 mg/d) versus aspirin (325 mg/d) for prevention of vascular events in patients with stroke or transient ischemic attack (Triflusal versus Aspirin in Cerebral Infarction Prevention [TACIP]). We assessed a combined end point (incidence of nonfatal ischemic stroke, nonfatal acute myocardial infarction, or vascular death) as well as the incidence of these events separately and the incidence of major hemorrhage.
RESULTS:
Of 2113 patients, 1058 received triflusal and 1055 aspirin. The mean follow-up period was 30.1 months. The incidence of combined end point (13.1% for triflusal, 12.4% for aspirin) as well the survival analysis (hazard ratio [HR] for triflusal versus aspirin, 1.09; 95% CI, 0.85 to 1.38) showed no differences between groups. The incidence of nonfatal stroke (HR, 1.09; 95% CI, 0.82 to 1.44), nonfatal acute myocardial infarction (HR, 0.95; 95% CI, 0.46 to 1.98,) and vascular death (HR, 1.22; 95% CI, 0.75 to 1.96) was also similar. A significantly higher incidence of major hemorrhages in the aspirin group was recorded (HR, 0.48; 95% CI, 0.28 to 0.82). The overall incidence of hemorrhage was significantly lower in the triflusal group (16.7% versus 25.2%) (odds ratio, 0.76; 95% CI, 0.67 to 0.86; P<0.001).
CONCLUSIONS:
This study failed to show significantly superior efficacy of triflusal over aspirin in the long-term prevention of vascular events after stroke, but triflusal was associated with a significantly lower rate of hemorrhagic complications.
AuthorsJordi Matías-Guiu, José M Ferro, José Alvarez-Sabín, Ferran Torres, M Dolores Jiménez, Aida Lago, Teresa Melo, TACIP Investigators
JournalStroke (Stroke) Vol. 34 Issue 4 Pg. 840-8 (Apr 2003) ISSN: 1524-4628 [Electronic] United States
PMID12649515 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Platelet Aggregation Inhibitors
  • Salicylates
  • triflusal
  • Aspirin
Topics
  • Aspirin (adverse effects, therapeutic use)
  • Cardiovascular Diseases (epidemiology, mortality, prevention & control)
  • Cerebral Infarction (diagnosis, drug therapy)
  • Double-Blind Method
  • Female
  • Hemorrhage (chemically induced)
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Myocardial Infarction (epidemiology)
  • Platelet Aggregation Inhibitors (adverse effects, therapeutic use)
  • Salicylates (adverse effects, therapeutic use)
  • Secondary Prevention
  • Stroke (epidemiology, prevention & control)
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: